Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma

BACKGROUND: Patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or R/R systemic anaplastic large-cell lymphoma (sALCL) treated with brentuximab vedotin (BV) experienced high remission rates in two Phase II trials. With increased response rates and survival times, patient-reported outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Robert, Allibone, Suzanne, Bartlett, Nancy L, Brice, Pauline, Chen, Andy, Pose, Katrina, Rich, Lynn, Bonthapally, Vijay, Garfin, Phillip M, Fanale, Michelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827881/
https://www.ncbi.nlm.nih.gov/pubmed/27103829
http://dx.doi.org/10.2147/OTT.S96175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827881/
https://www.ncbi.nlm.nih.gov/pubmed/27103829
http://dx.doi.org/10.2147/OTT.S96175

Ejemplares similares